Home

LeMaitre Vascular, Inc. - Common Stock (LMAT)

91.85
-8.06 (-8.07%)

Lemaitre Vascular is a medical device company focused on developing, manufacturing, and marketing innovative products for the treatment of vascular diseases

The company specializes in providing solutions for vascular surgeons, particularly in areas such as endovascular and open surgical procedures. Lemaitre Vascular offers a range of products, including synthetic grafts, stents, balloons, and devices used in the treatment of conditions such as peripheral artery disease and varicose veins. Through its commitment to research and development, the company aims to enhance patient outcomes and improve the effectiveness of vascular interventions.

SummaryNewsPress ReleasesChartHistoricalFAQ
LeMaitre (NASDAQ:LMAT) Misses Q4 Sales Targets, Stock Drops 11%
Medical device company LeMaitre Vascular (NASDAQLMAT) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 14% year on year to $55.72 million. Next quarter’s revenue guidance of $57.7 million underwhelmed, coming in 1.6% below analysts’ estimates. Its GAAP profit of $0.49 per share was in line with analysts’ consensus estimates.
Via StockStory · February 27, 2025
Earnings Scheduled For February 27, 2025benzinga.com
Via Benzinga · February 27, 2025
What To Expect From LeMaitre’s (LMAT) Q4 Earnings
Medical device company LeMaitre Vascular (NASDAQLMAT) will be announcing earnings results tomorrow after the bell. Here’s what to expect.
Via StockStory · February 26, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 17, 2024
Inari Medical Stock Gets RS Rating Upgradeinvestors.com
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.
Via Investor's Business Daily · December 11, 2024
Novocure Stock Earns 96 RS Ratinginvestors.com
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73.
Via Investor's Business Daily · December 3, 2024
In-Depth Examination Of 4 Analyst Recommendations For LeMaitre Vascularbenzinga.com
Via Benzinga · November 1, 2024
Analyst Scoreboard: 4 Ratings For LeMaitre Vascularbenzinga.com
Via Benzinga · October 15, 2024
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Yearinvestors.com
ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth.
Via Investor's Business Daily · November 18, 2024
Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Fridaybenzinga.com
Via Benzinga · November 1, 2024
This Synopsys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com
Via Benzinga · October 15, 2024
LMAT Stock Earnings: LeMaitre Vascular Beats EPS, Beats Revenue for Q2 2024investorplace.com
LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 1, 2024
Staar Surgical Stock Earns RS Rating Upgradeinvestors.com
On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77.
Via Investor's Business Daily · June 27, 2024
Navigating 4 Analyst Ratings For LeMaitre Vascularbenzinga.com
Via Benzinga · May 31, 2024
Recap: LeMaitre Vascular Q4 Earningsbenzinga.com
Via Benzinga · February 27, 2024
Earnings Scheduled For February 27, 2024benzinga.com
Companies Reporting Before The Bell • Gaotu Techedu (NYSEGOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via Benzinga · February 27, 2024
A Preview Of LeMaitre Vascular's Earningsbenzinga.com
Via Benzinga · February 26, 2024
Stryker Stock Sees RS Rating Treks Higher To 71investors.com
Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71.
Via Investor's Business Daily · May 29, 2024
Sell In May And Go Away? – April Dividend Income Reporttalkmarkets.com
The “Sell in May and Go Away” adage is wrong for most investors.
Via Talk Markets · May 27, 2024
LMAT Stock Earnings: LeMaitre Vascular Beats EPS, Beats Revenue for Q1 2024investorplace.com
LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 2, 2024
Inspire Medical Systems Stock Sees IBD RS Rating Rise To 78investors.com
On Tuesday, Inspire Medical Systems stock earned an upgrade to its Relative Strength (RS) Rating, from 69 to 78.
Via Investor's Business Daily · April 30, 2024
Barrington Research Maintains Outperform Rating for LeMaitre Vascular: Here's What You Need To Knowbenzinga.com
Via Benzinga · February 28, 2024
5 Analysts Have This to Say About LeMaitre Vascularbenzinga.com
Via Benzinga · October 23, 2023
Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Ratingbenzinga.com
Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQLMAT) with an Outperform rating and a 
Via Benzinga · September 6, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023benzinga.com
Via Benzinga · September 6, 2023